Inhibitors of Akt activity
AssigneeMerck & Co., Inc.
InventorsWilliam Robert Carling, Jose Luis Castro Pineiro, Kevin William Moore
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compounds comprising a triazolo[4,3-b]pyridazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
Claims7
A compound of the formula A:
- wherein
- R1 represents phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted with one, two or three substituents, independently selected from:
- a) halogen;
- b) C1-4 alkyl;
- c) C1-4 alkoxy;
- d) cyano;
- e) di(C1-4 alkyl)amino;
- f) hydroxy;
- R2 represents amino-C1-6 alkyl, C1-4 alkylamino-(C1-6)alkyl, di(C1-4 alkyl)amino-(C1-6)alkyl, or C1-4 alkoxy-(C1-6)alkyl;
- and
- R3 is selected from:
- C3-7 cycloalkyl and aryl;
- or a pharmaceutically acceptable salt or stereoisomer thereof.
A method for treating ovarian, pancreatic and breast cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound selected from 6-(2-hydroxyethyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-b]pyridazine, 6-(4-hydroxybutyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-b]pyridazine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.